Cannabis
iAnthus Annual General and Special Meeting of Shareholders
iAnthus Capital Holdings, Inc. (“iAnthus” or the “Company”) (CSE: IAN, OTCQX: ITHUF), which owns, operates, and partners with best-in-class regulated cannabis operations across the United States, is pleased to report the results for the Annual General & Special Meeting of Shareholders (the “Meeting”) of iAnthus held on Thursday, December 5, 2019 at 10:00 a.m. (Eastern Time).
iAnthus shareholders were asked to approve the election of directors, the appointment of Marcum LLP as auditors, and the special resolution to alter the Notice of Articles and the Articles of the Company. A detailed description of all matters voted on is contained in the Information Circular and Proxy Statement dated October 21, 2019. (“Information Circular”).
“I would like to thank our shareholders for their overwhelming support for our new, majority independent Board of Directors and be the first to welcome Robert Whelan, Michael Muldowney, Diane Ellis, Mark Dowley and Joy Chen to the iAnthus family. I would also like to thank our out-going Board members, Julius Kalcevich, Robert Galvin, Robert Petch and Paul Rosen for their past and continued support and guidance. Julius Kalcevich will continue in his leadership role at the Company as Chief Financial Officer,” stated Hadley Ford, CEO of iAnthus.
An aggregate of 88,227,439 common shares of iAnthus (being 51.4% of the common shares eligible to be voted at the Meeting) were represented at the Meeting. The vote on each matter was conducted by ballot. The manner in which the ballots were cast in respect of each matter is set out below.
1. Election of Directors:
The following eight nominees were elected to serve as directors of iAnthus until the next annual meeting of shareholders or until their successors are duly elected or appointed. Biographies for each of the upcoming board members can be found at www.newswire.ca/news-releases/ianthus-to-nominate-five-new-independent-directors-837614897.html.
Nominee |
Votes For |
% For |
Withheld |
% Withheld |
Against |
% Against |
Hadley Ford |
52,157,949 |
99.03% |
513,264 |
0.97% |
– |
– |
Randy Maslow |
51,840,939 |
98.42% |
830,274 |
1.58% |
– |
– |
Elizabeth Stavola |
51,853,572 |
98.45% |
817,641 |
1.55% |
– |
– |
Robert M. Whelan, Jr. |
52,184,835 |
99.08% |
486,378 |
0.92% |
– |
– |
Michael P. Muldowney |
52,170,321 |
99.05% |
500,892 |
0.95% |
– |
– |
Diane M. Ellis |
52,188,498 |
99.08% |
482,715 |
0.92% |
– |
– |
Mark Dowley |
52,170,752 |
99.05% |
500,461 |
0.95% |
– |
– |
Joy Chen |
52,184,318 |
99.08% |
486,895 |
0.92% |
– |
– |
2. Appointment of Auditors: |
87,035,843 |
98.79% |
1,066,049 |
1.21% |
– |
– |
3. Notice of Articles: |
51,987,073 |
98.70% |
– |
– |
684,140 |
1.30% |
SOURCE iAnthus Capital Holdings, Inc.
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
Cannabis
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
Cannabis
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
transfer1 week ago
IMC to transfer its Oranim Pharmacy shares back to the seller
-
Cannabis1 week ago
Right on Brands Announces Major Product Line Expansion via HONEY® Brands
-
Cannabis7 days ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis1 week ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
CCELL®2 weeks ago
CCELL Launches Environmentally Conscious Eco Star AIO Vaporizer
-
Innocan3 days ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf4 days ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis3 days ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care